Article

Clinical Pharmacology of Nicotine: Implications for Understanding, Preventing, and Treating Tobacco Addiction

Department of Medicine, University of California, San Francisco, California, USA.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.39). 05/2008; 83(4):531-41. DOI: 10.1038/clpt.2008.3
Source: PubMed

ABSTRACT Understanding the basic and clinical pharmacology of nicotine provides a basis for improved prevention and treatment of tobacco addiction. Nicotine acts on nicotinic cholinergic receptors in the brain to release dopamine and other neurotransmitters that sustain addiction. Neuroadaptation and tolerance involve changes in both nicotinic receptors and neural plasticity. Nicotine addiction can occur in the context of physical dependence characterized by self-medication to modulate negative affect and/or to relieve withdrawal symptoms, as well as, in light or occasional smokers, primarily for positive reinforcement in specific situations. Nicotine is metabolized primarily by CYP2A6. Its clearance exhibits considerable individual variability that is determined by genetic, racial, and hormonal (sex) factors. Genetically slow metabolism of nicotine appears to be associated with a lower level of dependence. Nicotine dependence is highly heritable and appears to be influenced by genes coding for some nicotine receptor subtypes, some neurotransmitter genes, and genes involved in neural connectivity. Novel pharmacotherapies for nicotine dependence include partial agonists for nicotinic receptors and nicotine vaccines. Pharmacogenetic studies suggest various candidate genes and a nicotine metabolism phenotype that influence outcome. Human pharmacology studies of nicotine and smoking behavior also provide a basis for assessing the benefits and risks of long-term nicotine use for harm reduction and for a potential cigarette regulatory strategy that includes reducing nicotine content of cigarettes to nonaddictive levels.

4 Followers
 · 
201 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Perceptions regarding the availability of smoking opportunities are known to affect cigarette craving; however, whether they impact actual smoking or how smokers respond to acute nicotine replacement therapy (NRT) administration is not known. This study examined the impact of pharmacological and expectancy components of NRT administration on craving and smoking in smokers anticipating or not anticipating an imminent smoking opportunity. Methods: 154 smokers (84 male) completed an experimental session in which instructions regarding the nicotine content of a lozenge (4mg vs. no nicotine) and regarding the availability of a future smoking opportunity were manipulated. Cigarette craving was assessed before and after manipulations and lozenge administration. All participants were then allotted one hour to self-administer as many cigarette puffs as they wished. Results: Unanticipated smoking opportunities reduced latency to self-administration (p<0.001), regardless of nicotine expectancy or pharmacology. When analyses included all participants, nicotine reduced intentions to smoke (p=0.016) and withdrawal-related craving (p=0.043) regardless of expectancy. Conversely, analyses using only “believers” of the nicotine content instructions revealed that nicotine expectancy reduced intentions to smoke (p=0.034) and withdrawal-related craving (p=0.047) regardless of actual nicotine administration. “Believers” also reported increased withdrawal-related craving when a smoking opportunity was perceived to be imminent (p=0.041). These effects were not significant when analyses included all participants. Conclusions: Findings suggest that unexpected smoking opportunities may be more appealing than expected ones regardless of perceived or actual acute NRT use. They also highlight the importance of reporting balanced placebo findings using all participants as well as “believers” only.
    Drug and alcohol dependence 02/2015; 147. DOI:10.1016/j.drugalcdep.2014.12.012 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Although the majority of substance use disorders depict reliable deficits in inhibitory control (IC), similar deficits are not consistently found in nicotine dependence. The mixed results of past research may have been due to confounding variables known to independently influence IC function, including age, concurrent drug use and particularly, length of nicotine abstinence. Methods A Stop Signal Task was used to examine Stop Signal Reaction Time (SSRT), a typical measure of IC, in nicotine dependence across two studies that attempted to closely control for IC confounds. Study 1 compared the SSRT of 37 dependent cigarette smokers (11 female) to 36 non-smokers (13 female), following 3-hours of nicotine abstinence. Study 2 compared 22 dependent cigarette smokers’ (11 female) SSRT scores when satiated on nicotine to their performance following 10-hours of nicotine abstinence. Results Nicotine dependent individuals did not differ from controls in SSRT performance following 3-hr abstinence, but showed a significant decline in performance following 10-hr abstinence, when compared to nicotine satiation. Conclusions During shorter abstinence periods, the acute benefits of nicotine satiation appear to facilitate inhibitory control, however IC was poorer during extended periods of nicotine abstinence. In turn, this suggests that the reliability of IC dysfunction in nicotine dependence varies according to abstinence length and needs to be carefully considered for future behavioural and neuroimaging examination of IC within this population.
    Drug and Alcohol Dependence 10/2014; 143. DOI:10.1016/j.drugalcdep.2014.07.008 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reduced craving associated with nicotine replacement therapy use is frequently attributed to the effects of nicotine pharmacology, however non-pharmacological factors may also play a role. This study examined the impact of nicotine pharmacology and non-pharmacological components of an acute nicotine lozenge (4 mg) on cigarette craving, mood and heart rate in 70 daily smokers (36 male). Smoking-related stimuli were used to assess cue-induced craving. Participants were randomly assigned to one of four conditions in a balanced placebo design where half the participants were provided deceptive information regarding the nicotine content of a lozenge. Subjective ratings of craving and mood were collected and heart rate was assessed before and after neutral and smoking cues. Nicotine expectancy reduced withdrawal-related craving (p=0.006) regardless of actual nicotine administration while combined nicotine expectancy and administration reduced intentions to smoke (p=0.046) relative to each of the other conditions. Exposure to smoking-related stimuli increased cigarette craving (p≤0.001) and negative affect (p≤0.001) regardless of expectancy or pharmacology. Following the smoking cue, women reported a greater increase in withdrawal-related craving than men (p=0.027). Findings suggest that both pharmacological and non-pharmacological components of nicotine lozenge administration contribute to its acute effects on craving, yet neither appears effective in preventing craving triggered by exposure to environmental smoking stimuli.
    Journal of Psychopharmacology 01/2014; 28(8). DOI:10.1177/0269881113519508 · 2.81 Impact Factor

Preview

Download
14 Downloads
Available from